Rallybio Corp Stock Alpha and Beta Analysis
| RLYB Stock | USD 1.19 0.03 2.59% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Rallybio Corp. It also helps investors analyze the systematic and unsystematic risks associated with investing in Rallybio Corp over a specified time horizon. Remember, high Rallybio Corp's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Rallybio Corp's market risk premium analysis include:
Beta 0.24 | Alpha 0.11 | Risk 2.94 | Sharpe Ratio 0.0568 | Expected Return 0.17 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Rallybio |
Rallybio Corp Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Rallybio Corp market risk premium is the additional return an investor will receive from holding Rallybio Corp long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Rallybio Corp. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Rallybio Corp's performance over market.| α | 0.11 | β | 0.24 |
Rallybio Corp expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Rallybio Corp's Buy-and-hold return. Our buy-and-hold chart shows how Rallybio Corp performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Rallybio Corp Market Price Analysis
Market price analysis indicators help investors to evaluate how Rallybio Corp stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Rallybio Corp shares will generate the highest return on investment. By understating and applying Rallybio Corp stock market price indicators, traders can identify Rallybio Corp position entry and exit signals to maximize returns.
Rallybio Corp Return and Market Media
The median price of Rallybio Corp for the period between Thu, Sep 12, 2024 and Wed, Dec 11, 2024 is 1.1 with a coefficient of variation of 4.91. The daily time series for the period is distributed with a sample standard deviation of 0.05, arithmetic mean of 1.07, and mean deviation of 0.04. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of H... | 09/23/2024 |
2 | Acquisition by Hunt Ronald of 16500 shares of Rallybio Corp at 1.91 subject to Rule 16b-3 | 10/16/2024 |
3 | Rallybio Co. Receives 10.00 Average Price Target from Brokerages | 10/21/2024 |
4 | Acquisition by Nash Christine A of 15490 shares of Rallybio Corp at 5.64 subject to Rule 16b-3 | 11/20/2024 |
5 | Rallybios SWOT analysis rare disease biotech stock advances FNAIT treatment | 11/25/2024 |
6 | Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women | 11/27/2024 |
7 | Rallybio to Initiate RLYB116 Confirmatory Clinical PKPD Study in Second Quarter 2025 | 12/02/2024 |
8 | Acquisition by Uden Stephen of 62000 shares of Rallybio Corp at 15.04 subject to Rule 16b-3 | 12/06/2024 |
9 | Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting | 12/10/2024 |
About Rallybio Corp Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Rallybio or other stocks. Alpha measures the amount that position in Rallybio Corp has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2022 | 2023 | 2024 (projected) | Current Ratio | 27.61 | 16.71 | 12.39 | 13.82 | Net Debt To EBITDA | 3.86 | 0.86 | 0.33 | 0.32 |
Rallybio Corp Upcoming Company Events
As portrayed in its financial statements, the presentation of Rallybio Corp's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Rallybio Corp's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Rallybio Corp's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Rallybio Corp. Please utilize our Beneish M Score to check the likelihood of Rallybio Corp's management manipulating its earnings.
| 4th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Rallybio Corp
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Rallybio Corp Backtesting, Rallybio Corp Valuation, Rallybio Corp Correlation, Rallybio Corp Hype Analysis, Rallybio Corp Volatility, Rallybio Corp History and analyze Rallybio Corp Performance. For information on how to trade Rallybio Stock refer to our How to Trade Rallybio Stock guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Rallybio Corp technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.